Journal Article
. 2019 Feb;20(3).
doi: 10.1016/S1470-2045(18)30862-3.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Michael Gnant 1 Georg Pfeiler 2 Günther G Steger 3 Daniel Egle 4 Richard Greil 5 Florian Fitzal 6 Viktor Wette 7 Marija Balic 8 Ferdinand Haslbauer 9 Elisabeth Melbinger-Zeinitzer 10 Vesna Bjelic-Radisic 11 Raimund Jakesz 12 Christian Marth 4 Paul Sevelda 13 Brigitte Mlineritsch 14 Ruth Exner 12 Christian Fesl 15 Sophie Frantal 15 Christian F Singer 2 Austrian Breast and Colorectal Cancer Study Group  
  • PMID: 30795951
  •     22 citations


Background: In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures. Results from the ABCSG-18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures. Disease-free survival outcomes from ABCSG-18 have not yet been reported.

Methods: Postmenopausal patients with early, hormone receptor-positive, non-metastatic adenocarcinoma of the breast, who had completed their initial adjuvant treatment pathway (surgery, radiotherapy, or chemotherapy, or a combination) and were receiving adjuvant aromatase inhibitors, were enrolled at 58 trial centres in Austria and Sweden into this prospective, double-blind, placebo-controlled, phase 3 trial. With permuted block randomisation (block sizes 2 and 4, stratified by previous aromatase inhibitor use, total lumbar spine bone mineral density score at baseline, and type of centre), patients were assigned (1:1) to receive subcutaneous denosumab (60 mg) or matching placebo every 6 months during aromatase inhibitor therapy. The primary endpoint (previously reported) was the time to first clinical fracture after randomisation. The secondary endpoint reported here is disease-free survival (defined as time from randomisation to first evidence of local or distant metastasis, contralateral breast cancer, secondary carcinoma, or death from any cause) in the intention-to-treat population. This study is registered with EudraCT (number 2005-005275-15) and (number NCT00556374), and is ongoing for long-term follow-up.

Findings: Between Dec 18, 2006, and July 22, 2013, 3425 eligible patients were enrolled and randomly assigned; 1711 to the denosumab group and 1709 to the placebo group (with five others withdrawing consent). After a median follow-up of 73 months (IQR 58-95), 240 (14·0%) patients in the denosumab and 287 (16·8%) in the placebo group had disease-free survival events. Disease-free survival was significantly improved in the denosumab group versus the placebo group (hazard ratio 0·82, 95% CI 0·69-0·98, Cox p=0·0260; descriptive analysis, without controlling for multiplicity). In the denosumab group, disease-free survival was 89·2% (95% CI 87·6-90·8) at 5 years and 80·6% (78·1-83·1) at 8 years of follow-up, compared with 87·3% (85·7-89·0) at 5 years and 77·5% (74·8-80·2) and 8 years in the placebo group. No independently adjudicated cases of osteonecrosis of the jaw or confirmed atypical femoral fractures were recorded. The total number of adverse events was similar in the denosumab group (1367 [including 521 serious] adverse events) and the placebo group (1339 [515 serious]). The most common serious adverse events were osteoarthritis (62 [3·6%] of 1709 in the denosumab group vs 58 [3·4%] of 1690 in the placebo group), meniscus injury (23 [1·3%] vs 24 [1·4%]), and cataract (16 [0·9%] vs 28 [1·7%]). One (<0·1%) treatment-related death (due to pneumonia, septic kidney failure, and cardiac decompensation) occurred in the denosumab group.

Interpretation: Denosumab constitutes an effective and safe adjuvant treatment for patients with postmenopausal hormone receptor-positive early breast cancer receiving aromatase inhibitor therapy.

Funding: Amgen.

St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.
Marija Balic, Christoph Thomssen, +2 authors, Nadia Harbeck.
Breast Care (Basel), 2019 Dec 05; 14(2). PMID: 31798382    Free PMC article.
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
Diana Lüftner, Ingo Bauerfeind, +21 authors, Marc Thill.
Breast Care (Basel), 2019 Dec 05; 14(5). PMID: 31798392    Free PMC article.
Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies.
Andreas Schneeweiss, Andreas D Hartkopf, +16 authors, Florian Schütz.
Geburtshilfe Frauenheilkd, 2020 Mar 07; 80(3). PMID: 32139917    Free PMC article.
Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.
Hemin Lee, Yinzhu Jin, +4 authors, Seoyoung C Kim.
Drugs Aging, 2020 Feb 07; 37(4). PMID: 32026309
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
Irene E G van Hellemond, Carolien H Smorenburg, +14 authors, Dutch Breast Cancer Research Group (BOOG).
Breast Cancer Res Treat, 2020 Mar 04; 180(3). PMID: 32124136    Free PMC article.
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer.
Stella D'Oronzo, Erica Silvestris, +2 authors, Marco Tucci.
Int J Mol Sci, 2020 Apr 30; 21(8). PMID: 32344743    Free PMC article.
Current and Emerging Biomarkers Predicting Bone Metastasis Development.
Michele Iuliani, Sonia Simonetti, +5 authors, Daniele Santini.
Front Oncol, 2020 Jun 26; 10. PMID: 32582538    Free PMC article.
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Julie R Gralow, William E Barlow, +20 authors, Gabriel N Hortobagyi.
J Natl Cancer Inst, 2019 Nov 07; 112(7). PMID: 31693129    Free PMC article.
Management of hormone receptor-positive, HER2-negative early breast cancer.
Elaine M Walsh, Karen L Smith, Vered Stearns.
Semin Oncol, 2020 Jun 18; 47(4). PMID: 32546323    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.
Marc Thill, Christian Jackisch, +42 authors, Nina Ditsch.
Breast Care (Basel), 2019 Sep 29; 14(4). PMID: 31558898    Free PMC article.
Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.
Jie Ming, Shane J F Cronin, Josef M Penninger.
Front Oncol, 2020 Aug 28; 10. PMID: 32850393    Free PMC article.
More is not always better-what can be learned from the D-CARE trial.
Georg Pfeiler, Michael Gnant.
Ann Transl Med, 2020 Sep 22; 8(16). PMID: 32953834    Free PMC article.
Caring about bone-modifying agents (BMAs) in women with early-stage breast cancer.
Charles L Shapiro.
Ann Transl Med, 2020 Sep 22; 8(16). PMID: 32953838    Free PMC article.
Atypical femoral fractures from bisphosphonate in cancer patients - Review.
Matthew Lockwood, Rajesh Banderudrappagari, Larry J Suva, Issam Makhoul.
J Bone Oncol, 2019 Sep 10; 18. PMID: 31497503    Free PMC article.
Yoshitaka Arase, Tatehiro Kagawa, Atsushi Tanaka.
Hepatology, 2019 Dec 22; 72(1). PMID: 31863598    Free PMC article.
Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions.
Christopher N George, Victor Canuas-Landero, +3 authors, Penelope Ottewell.
J Bone Oncol, 2020 Oct 01; 25. PMID: 32995253    Free PMC article.
Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
Nora Pashayan, Antonis C Antoniou, +31 authors, Martin Widschwendter.
Nat Rev Clin Oncol, 2020 Jun 20; 17(11). PMID: 32555420    Free PMC article.
How Different Are the Molecular Mechanisms of Nodal and Distant Metastasis in Luminal A Breast Cancer?
Petr Lapcik, Anna Pospisilova, +3 authors, Pavel Bouchal.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947901    Free PMC article.
A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic.
H R Sapkota, A Nune, J Bateman, S Venkatachalam.
Osteoporos Int, 2020 Nov 05;. PMID: 33146750    Free PMC article.
Osteocytes and Bone Metastasis.
Manuel A Riquelme, Eduardo R Cardenas, Jean X Jiang.
Front Endocrinol (Lausanne), 2020 Nov 10; 11. PMID: 33162934    Free PMC article.
Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments.
Charles L Shapiro.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114141    Free PMC article.
Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?
Alisson Clemenceau, Laetitia Michou, Caroline Diorio, Francine Durocher.
Int J Mol Sci, 2020 Nov 19; 21(22). PMID: 33203195    Free PMC article.